Atyr Pharma To Present At Upcoming Investor Conferences

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025.

Details of the conferences appear below:

Conference: RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 21, 2025
Time: 11:00am EDT
Location: New York, NY
Format: Fireside Chat

Conference: Piper Sandler 3^rd Annual Virtual Lung Symposium with ATS Takeaways
Date: Tuesday, May 27, 2025
Time: 2:00pm EDT
Location: Virtual
Format: Fireside Chat

Conference: Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 2:00pm EDT
Location: New York, NY
Format: Fireside Chat

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

Frequently Asked Questions

What is aTyr Pharma?

aTyr Pharma is a clinical-stage biotechnology company developing first-in-class medicines from its tRNA synthetase platform, targeting fibrosis and inflammation.

What is efzofitimod?

Efzofitimod is aTyr's lead therapeutic candidate, a biologic immunomodulator in clinical development for interstitial lung disease.

Where can I find more information about aTyr Pharma?

Visit aTyr Pharma's website at www.atyrpharma.com for more information.

First published on Tue, May 20, 2025

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

aTyr Pharma biotechnology tRNA synthetase fibrosis inflammation efzofitimod interstitial lung disease investor conferences

Join The Discussion

- Promoted By TechDogs -

Biotechnology